Venture Capital Informazioni 206, Piazza San Carlo Torino Italia Ciro Spedaliere, Pietro Puglisi +39 / 011 3325889 info@clarisventures.com http://www.clarisventures.com Struttura Numero di Executives:3 Numero di fondi:2 Numero di fondi art. 8 SFDR:1 Numero di fondi art. 9 SFDR:N.A. Totale capitale gestito:€170.000.000 Numero di portfolio companies:11 Policy di investimento Investimento minimo:1.000.000 € Investimento massimo:5.000.000 € Preferenze geografiche:Italy Focus di investimento:Early Stage Preferenze di settore:Biotech Remarks Claris Ventures is a venture capital operator based in Italy specialized in early stage investments in companies active in the development of new drugs with high potential, born from the Italian research network – both local and international. The objective of Claris Ventures is to identify and support innovations in the pharmaceutical field, investing in new companies that develop potential drugs that can revolutionize the current treatment scenario in indications with limited therapeutic alternatives. The investment strategy is focused on biotech projects ready to start clinical studies in which Claris Ventures will provide the resources to fund the eventual completion of preclinical studies and a first human study. Venture Capital Informazioni 206, Piazza San CarloTorinoItalia Ciro Spedaliere, Pietro Puglisi +39 / 011 3325889 info@clarisventures.com http://www.clarisventures.com Remarks Claris Ventures is a venture capital operator based in Italy specialized in early stage investments in companies active in the development of new drugs with high potential, born from the Italian research network – both local and international. The objective of Claris Ventures is to identify and support innovations in the pharmaceutical field, investing in new companies that develop potential drugs that can revolutionize the current treatment scenario in indications with limited therapeutic alternatives. The investment strategy is focused on biotech projects ready to start clinical studies in which Claris Ventures will provide the resources to fund the eventual completion of preclinical studies and a first human study.